Skip to main content

Bevacizumab Biosimilar Demonstrates Therapeutic Equivalence to Reference Drug in Patients with Late-Stage NSCLC

TOP - October 2021 Vol 14, No 6 | Biosimilars

Results from a phase 3 clinical trial showed equivalence between the bevacizumab biosimilar, BCD-021, and the reference product, bevacizumab (Avastin), in terms of overall response rate (ORR) in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer. Safety, pharmacokinetics (PK), and immunogenicity parameters were also comparable between the 2 agents. These findings were reported in a poster presentation by Natalia Fadeeva, MD, PhD, Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine, Russia, and colleagues during the 2021 European Society for Medical Oncology virtual meeting.

A total of 357 patients from Russia and India were randomized 1:1 and 2:1, respectively, to receive either BCD-201 or reference bevacizumab plus paclitaxel and carboplatin once every 3 weeks for 6 cycles. Patients had at least 1 computed tomography scan after initiation of therapy. At week 18, patients who had stable disease or who acheived a complete or partial response were given the opportunity to continue treatment with BCD-021 until disease progression, death, or intolerable toxicity.

The primary efficacy end point was ORR based on responses achieved by week 19 and confirmed 4 weeks thereafter. The primary PK end point was AUC(0-t) after first infusion. Secondary end points included safety, PK, and immunogenicity.

Results showed an ORR of 34.6% in the BCD-021 group and 33.8% in the reference bevacizumab group. Complete response rates were 1.5% and 0.7%, respectively, and partial response rates were 33.2% and 33.1%, respectively. The percentage of patients with stable disease in the biosimilar and reference drug groups were 31.7% and 33.8%, respectively.

PK parameters and the incidence of antidrug antibodies were also comparable between BCD-021 and reference bevacizumab.

The rates of any grade adverse events (AEs) were 91.3% in the BCD-021 group versus 93.4% in the reference bevacizumab group. Serious AEs were observed in 13.6% and 10.9% of patients, respectively. The most frequently occurring AEs were anemia, neutropenia, and alopecia.

“This study demonstrated equivalence between BCD-021 and bevacizumab in terms of ORR risk difference and risk ratio. PK equivalence of BCD-021 and bevacizumab was also confirmed. Safety and immunogenicity parameters were comparable between BCD-021 and bevacizumab,” noted Dr Fadeeva and colleagues in their poster.

Get TOP in Your Inbox

Stay up to date with the latest oncology pharmacy news and insights by subscribing to our e-newsletter!


Related Items